Abstract
Cancer development is influenced by genetic factors and modifiable exposures. GWAS has identified genetic variants and developed of prediction models through Polygenic Risk Scores (PRS), but PRS alone has limitations for estimating cancer risk.
This study assesses a novel PRS constellation approach that integrates Polygenic Risk Scores (PRS) from both lifestyle and genetic traits to enhance prediction models for colorectal, breast, and prostate cancers. The approach was developed using the UK Biobank dataset and validated in the independent GenRisk cohort.
The model, incorporating sex and age, achieved AUCs of 0.74 for CRC, 0.65 for BC, and 0.75 for PC in the UK Biobank. Including tumor-related PRSs improved PC prediction but had limited impact on CRC and BC. Age and sex inclusion boosted CRC and PC model accuracy. However, GenRisk validation showed reduced AUCs and limited utility of lifestyle PRSs, with CRC and BC models achieving 0.62 and PC 0.56.
Integrating lifestyle-related characteristics into PRS does not significantly enhance cancer-specific PRS prediction. However, PRSs for these traits show independent predictive power, highlighting the importance of considering lifestyle in cancer risk and the need for precision medicine to improve early detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
VM received grants from Instituto de Salud Carlos III I, co–funded by FEDER funds a way to build Europe (grants PI17–00092 and PI20/01439); the Scientific Foundation of the Spanish Association Against Cancer (grant GCTRA18022MORE); the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), action GenRisk. This study has been funded by Instituto de Salud Carlos III (ISCIII), Programa FORTALECE del Ministerio de Ciencia e Innovación, through the project number FORT23/00032. BRS received a PhD fellowship from Instituto de Salud Carlos III (FI21/00056). ADV was funded by the Catalan PERIS program (fellowship SLT017/20/000042).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank study received ethical approval from the North West Centre for Research Ethics Committee (11/NW/0382) and had obtained written informed consent from all participants. The protocol of GenRisk was approved by each of the ethics committees of the participating institutions. The specific study reported here was approved by the Bellvitge Hospital Ethics Committee with reference PR020/17. Informed consent was obtained from all individual participants included in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
This study utilizes information sourced from the UK Biobank repository (application number 69033), accessible upon request submission to the UK Biobank. For further details, visit https://www.ukbiobank.ac.uk. The GenRisk data can be obtained for research purposes applying for access to the corresponding author, subject to approval by the GenRisk Data Access Committee.
